Psoriasis – Pipeline Review, H1 2017, provides an overview of the Psoriasis (Immunology) pipeline landscape.
Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/276740 .
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Psoriasis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 21, 44, 42, 1, 103, 32 and 9 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 6 molecules, respectively.
Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Browse the full report @ http://www.orbisresearch.com/reports/index/psoriasis-pipeline-review-h1-2017 .
– The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
– The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/276740 .
AbGenomics International Inc
Addex Therapeutics Ltd
Adello Biologics LLC
Advinus Therapeutics Ltd
Albireo Pharma Inc
Anacor Pharmaceuticals Inc
Arbor Pharmaceuticals LLC
Arena Pharmaceuticals Inc
Argos Therapeutics Inc
Arrien Pharmaceuticals LLC
Atlantic Bio Sci LLC
Aurigene Discovery Technologies Ltd
Aurinia Pharmaceuticals Inc
Beta Pharma Inc
Biomics Biotechnologies Co Ltd
Boehringer Ingelheim GmbH
Brickell Biotech Inc
Bristol-Myers Squibb Company
C4X Discovery Holdings PLC
Can-Fite BioPharma Ltd
Cell Medica Ltd
Chipscreen Biosciences Ltd
Coherus BioSciences Inc
Concenter BioPharma Silkim Ltd
Crescita Therapeutics Inc
Dr. August Wolff GmbH & Co KG Arzneimittle
EA Pharma Co Ltd
Eli Lilly and Company
Foamix Pharmaceuticals Ltd
Forward Pharma A/S
Galectin Therapeutics Inc
Gem Pharmaceuticals LLC
Genor BioPharma Co Ltd
Grupo Ferrer Internacional SA
Huabo Biopharm Co Ltd
Hydra Biosciences Inc
iCo Therapeutics Inc.
Immune Pharmaceuticals Inc
Immune Response BioPharma Inc
Japan Tobacco Inc
Jenrin Discovery Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kadmon Corp LLC
KaloBios Pharmaceuticals Inc
Kang Stem Biotech Co Ltd
KPI Therapeutics Inc
Lead Pharma Holding BV
LEO Pharma A/S
Maruho Co Ltd
Medestea Research & Production SpA
Mitsubishi Tanabe Pharma Corp
Momenta Pharmaceuticals Inc
Mycenax Biotech Inc
Nimbus Therapeutics LLC
NovaLead Pharma Pvt Ltd
Numab Innovation AG
Panacea Biotec Ltd
Pharis Biotec GmbH
Principia Biopharma Inc
Promius Pharma LLC
Protalix BioTherapeutics Inc
Prothena Corp Plc
Provectus Biopharmaceuticals Inc
Qilu Pharmaceutical Co Ltd
RedHill Biopharma Ltd
Reliance Life Sciences Pvt Ltd
Rigel Pharmaceuticals Inc
Rock Creek Pharmaceuticals, Inc.
Sandoz International GmbH
Sareum Holdings Plc
SBI Biotech Co Ltd
Shulov Innovative Science Ltd
Sigmoid Pharma Ltd
Spherium Biomed SL
sterna biologicals Gmbh & Co KG
Sun Pharma Advanced Research Company Ltd
SWITCH Biotech LLC
Syntrix Biosystems Inc
Takeda Pharmaceutical Company Ltd
Tasly Pharmaceutical Group Co Ltd
Teva Pharmaceutical Industries Ltd
Tolero Pharmaceuticals Inc
Valeant Pharmaceuticals International Inc
vTv Therapeutics Inc
Wellstat Therapeutics Corp
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact firstname.lastname@example.org